Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s488, 2024. DOI: 10.25251/skin.8.supp.488. Disponível em: https://skin.dermsquared.com/skin/article/view/3132. Acesso em: 19 may. 2026.